426 related articles for article (PubMed ID: 12373528)
1. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Verhagen Metman L
Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
[TBL] [Abstract][Full Text] [Related]
2. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Oh JD; Chase TN
Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
[TBL] [Abstract][Full Text] [Related]
3. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of motor fluctuations in Parkinson's disease.
Widnell K
Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
[TBL] [Abstract][Full Text] [Related]
5. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
McColl CD; Reardon KA; Shiff M; Kempster PA
Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
[TBL] [Abstract][Full Text] [Related]
6. The evolution and origin of motor complications in Parkinson's disease.
Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
[TBL] [Abstract][Full Text] [Related]
7. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
10. When do levodopa motor fluctuations first appear in Parkinson's disease?
Stocchi F; Jenner P; Obeso JA
Eur Neurol; 2010; 63(5):257-66. PubMed ID: 20332641
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological therapy of complicated Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
[TBL] [Abstract][Full Text] [Related]
12. Problems with current pharmacologic treatment of Parkinson's disease.
Hurtig HI
Exp Neurol; 1997 Mar; 144(1):10-6. PubMed ID: 9126144
[TBL] [Abstract][Full Text] [Related]
13. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
Tse W
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
[TBL] [Abstract][Full Text] [Related]
14. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
15. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
[TBL] [Abstract][Full Text] [Related]
16. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
17. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Gottwald MD
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
[TBL] [Abstract][Full Text] [Related]
18. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
19. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Cedarbaum JM
Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]